Comparing the effect of a twice-weekly tacrolimus and betamethasone valerate dose on the subclinical epidermal barrier defect in atopic dermatitis

Acta Dermato-Venereologica

Volumn 95, Issue 6, 2015, Pages 653-658

  Chittock, John ^a   Brown, Kirsty ^a   Cork, Michael J ^a,b   Danby, Simon G ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Corticosteroid; Epidermal barrier; Topical; Topical calcineurin inhibitor

Indexed keywords

BETAMETHASONE VALERATE; BIOLOGICAL MARKER; KALLIKREIN 14; KALLIKREIN 5; STRATUM CORNEUM CHYMOTRYPTIC ENZYME; TACROLIMUS; TRYPTASE; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; CALCINEURIN INHIBITOR; OINTMENT; PEPTIDE HYDROLASE; SKIN CREAM;

AREA UNDER THE CURVE; ARTICLE; ATOPIC DERMATITIS; BIOPHYSICS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; EPIDERMIS; HUMAN; HYDRATION; OBSERVATIONAL STUDY; PERMEABILITY BARRIER; PH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN SURFACE; STRATUM CORNEUM; ADMINISTRATION AND DOSAGE; ADULT; CHEMISTRY; COMPARATIVE STUDY; DENSITOMETRY; DERMATITIS, ATOPIC; DRUG EFFECTS; ELECTRIC CAPACITANCE; ENZYMOLOGY; FUNCTIONS OF THE SKIN AND ITS APPENDAGES; METABOLISM; OINTMENT; PATHOPHYSIOLOGY; SINGLE BLIND PROCEDURE; THERMOREGULATION;

ADULT; ANTI-INFLAMMATORY AGENTS; BETAMETHASONE VALERATE; CALCINEURIN INHIBITORS; DENSITOMETRY; DERMATITIS, ATOPIC; ELECTRIC CAPACITANCE; EPIDERMIS; HUMANS; HYDROGEN-ION CONCENTRATION; OINTMENTS; PEPTIDE HYDROLASES; SINGLE-BLIND METHOD; SKIN CREAM; SKIN PHYSIOLOGICAL PHENOMENA; TACROLIMUS; WATER LOSS, INSENSIBLE;

EID: 84932097914     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-2048     Document Type: Article

References (37)

1. Danby SG, Cork MJ. A new understanding of atopic dermatitis: The role of epidermal barrier dysfunction and subclinical inflammation. J Clin Dermatol 2010; 1: 33-46.
2. Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol 2008; 121: 1337-1343.
3. Guttman-Yassky E, Suarez-Farinas M, Chiricozzi A, Nograles KE, Shemer A, Fuentes-Duculan J, et al. Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. J Allergy Clin Immunol 2009; 124: 1235-1244.
4. Jensen JM, Folster-Holst R, Baranowsky A, Schunck M, Winoto-Morbach S, Neumann C, et al. Impaired sphingomyelinase activity and epidermal differentiation in atopic dermatitis. J Invest Dermatol 2004; 122: 1423-1431.
5. Voegeli R, Rawlings AV, Breternitz M, Doppler S, Schreier T, Fluhr JW. Increased stratum corneum serine protease activity in acute eczematous atopic skin. Br J Dermatol 2009; 161: 70-77.
6. Daehnhardt-Pfeiffer S, Surber C, Wilhelm KP, Daehnhardt D, Springmann G, Boettcher M, et al. Noninvasive stratum corneum sampling and electron microscopical examination of skin barrier integrity: pilot study with a topical glycerin formulation for atopic dermatitis. Skin Pharmacol Physiol 2012; 25: 155-161.
7. Mocsai G, Gaspar K, Nagy G, Irinyi B, Kapitany A, Biro T, et al. Severe skin inflammation and filaggrin mutation similarly alter the skin barrier in patients with atopic dermatitis. Br J Dermatol 2014; 170: 617-624.
8. Danby SG, Chittock J, Brown K, Albenali LH, Cork MJ. The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis. Br J Dermatol 2014; 170: 914-921.
9. Suarez-Farinas M, Tintle SJ, Shemer A, Chiricozzi A, Nograles K, Cardinale I, et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol 2011; 127: 954-964.
10. Eichenfield LF, Totri C. Optimizing outcomes for paediatric atopic dermatitis. Br J Dermatol 2014; 170: 31-37.
11. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012; 26: 1045-1060.
12. Reitamo S, Remitz A. An update on current pharmacotherapy options in atopic dermatitis. Expert Opin Pharmacother 2014; 15: 1517-1524.
13. Tang TS, Bieber T, Williams HC. Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful? J Allergy Clin Immunol 2014; 133: 1615-1625.
14. Williams HC. Preventing eczema flares with topical corticosteroids or tacrolimus: which is best? Br J Dermatol 2011; 164: 231-233.
15. Jensen JM, Pfeiffer S, Witt M, Brautigam M, Neumann C, Weichenthal M, et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol 2009; 123: 1124-1133.
16. Kao JS, Fluhr JW, Man MQ, Fowler AJ, Hachem JP, Crumrine D, et al. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol 2003; 120: 456-464.
17. Kim M, Jung M, Hong SP, Jeon H, Kim MJ, Cho MY, et al. Topical calcineurin inhibitors compromise stratum corneum integrity, epidermal permeability and antimicrobial barrier function. Exp Dermatol 2010; 19: 501-510.
18. Breternitz M, Flach M, Prassler J, Elsner P, Fluhr JW. Acute barrier disruption by adhesive tapes is influenced by pressure, time and anatomical location: integrity and cohesion assessed by sequential tape stripping. A randomized, con- trolled study. Br J Dermatol 2007; 156: 231-240.
19. Fluhr JW, Feingold KR, Elias PM. Transepidermal water loss reflects permeability barrier status: validation in human and rodent in vivo and ex vivo models. Exp Dermatol 2006; 15: 483-492.
20. Imhof RE, De Jesus ME, Xiao P, Ciortea LI, Berg EP. Closed-chamber transepidermal water loss measurement: microclimate, calibration and performance. Int J Cosmet Sci 2009; 31: 97-118.
21. Aschoff R, Schwanebeck U, Brautigam M, Meurer M. Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1% in patients with mild-to-moderate atopic dermatitis. Exp Dermatol 2009; 18: 24-29.
22. Dahnhardt-Pfeiffer S, Dahnhardt D, Buchner M, Walter K, Proksch E, Fölster-Holst R. Comparison of effects of tacrolimus ointment and mometasone furoate cream on the epidermal barrier of patients with atopic dermatitis. J Dtsch Dermatol Ges 2013; 11: 437-443.
23. Jensen JM, Weppner M, Dahnhardt-Pfeiffer S, Neumann C, Brautigam M, Schwarz T, et al. Effects of pimecrolimus compared with triamcinolone acetonide cream on skin barrier structure in atopic dermatitis: a randomized, double-blind, right-left arm trial. Acta Derm Venereol 2013; 93: 515-519.
24. Man MQ, Hatano Y, Lee SH, Man M, Chang S, Feingold KR, et al. Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges. J Invest Dermatol 2008; 128: 79-86.
25. Jensen JM, Scherer A, Wanke C, Brautigam M, Bongiovanni S, Letzkus M, et al. Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis. Allergy 2012; 67: 413-423.
26. Koch PJ, de Viragh PA, Scharer E, Bundman D, Longley MA, Bickenbach J, et al. Lessons from loricrin-deficient mice: compensatory mechanisms maintaining skin barrier function in the absence of a major cornified envelope protein. J Cell Biol 2000; 151: 389-400.
27. Ghadially R, Halkier-Sorensen L, Elias PM. Effects of petrolatum on stratum corneum structure and function. J Am Acad Dermatol 1992; 26: 387-396.
28. Matsumoto T, Yuasa H, Kai R, Ueda H, Ogura S, Honda Y. Skin capacitance in normal and atopic infants, and effects of moisturizers on atopic skin. J Dermatol 2007; 34: 447-450.
29. Voegeli R, Heiland J, Doppler S, Rawlings AV, Schreier T. Efficient and simple quantification of stratum corneum proteins on tape strippings by infrared densitometry. Skin Res Technol 2007; 13: 242-251.
30. Hachem JP, Man MQ, Crumrine D, Uchida Y, Brown BE, Rogiers V, et al. Sustained serine proteases activity by prolonged increase in pH leads to degradation of lipid processing enzymes and profound alterations of barrier function and stratum corneum integrity. J Invest Dermatol 2005; 125: 510-520.
31. Caubet C, Jonca N, Brattsand M, Guerrin M, Bernard D, Schmidt R, et al. Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/ KLK5/hK5 and SCCE/KLK7/hK7. J Invest Dermatol 2004; 122: 1235-1244.
32. Sakabe J, Yamamoto M, Hirakawa S, Motoyama A, Ohta I, Tatsuno K, et al. Kallikrein-related Peptidase 5 Functions in proteolytic processing of profilaggrin in cultured human keratinocytes. J Biol Chem 2013; 288: 17179-17189.
33. Yamamoto M, Miyai M, Matsumoto Y, Tsuboi R, Hibino T. Kallikrein-related peptidase-7 regulates caspase-14 maturation during keratinocyte terminal differentiation by generating an intermediate form. J Biol Chem 2012; 287: 32825-32834.
34. Hansson L, Backman A, Ny A, Edlund M, Ekholm E, Ekstrand Hammarstrom B, et al. Epidermal overexpression of stratum corneum chymotryptic enzyme in mice: a model for chronic itchy dermatitis. J Invest Dermatol 2002; 118: 444-449.
35. Furio L, de Veer S, Jaillet M, Briot A, Robin A, Deraison C, et al. Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome. J Exp Med 2014; 211: 499-513.
36. Bieber T, Cork M, Reitamo S. Atopic dermatitis: a candidate for disease-modifying strategy. Allergy 2012; 67: 969-975.
37. Williams HC, Chalmers JR, Simpson EL. Prevention of atopic dermatitis. F1000 Med Rep 2012; 4: 24.